Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Einav G. Levin"'
Autor:
Hila Magen, Abraham Avigdor, Lee Nevo, Shalev Fried, Amit Gibori, Einav G Levin, Yaniv Lustig, Eden Shkury, Galia Rahav
Publikováno v:
PLoS ONE, Vol 18, Iss 5, p e0284925 (2023)
Patients with plasma cell disorders (PCD) are at an increased risk for severe morbidity and mortality due to COVID-19. Recent data have suggested that patients with hematological malignancies, including those with PCD, have suboptimal antibody respon
Externí odkaz:
https://doaj.org/article/d9adb0c1b39542be959dd8b59e562969
Autor:
Einav G. Levin, Sharon Tzelnick, Daniel Yaacobi, Igor Vainer, Aviram Mizrachi, Aron Popovtzer, Ethan Soudry
Publikováno v:
Acta Otorhinolaryngologica Italica. 43:203-211
Autor:
Keren Tsaraf, Yaniv Lustig, Einav G Levin, Itzchak Levy, Yana Davidov, Mariya Likhter, Orna Mor, Oranit Cohen-Ezra, Galia Rahav, Ziv Ben Ari, Gil Ben Yakov
Publikováno v:
Liver Transplantation
The BNT162b2 messenger RNA (mRNA) vaccine against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been shown to be safe and effective in immunocompetent patients. The safety and efficacy of this vaccine in liver transplantation (
Autor:
Gili Regev-Yochay, Victoria Indenbaum, Carmit Rubin, Adina Bar-Chaim, Yaniv Lustig, Michal Mandelboim, Einav G Levin, Moriah Bergwerk, Neta S. Zuckerman, Tal Gonen, Sharon Amit, Yitshak Kreiss, Marc Lipsitch, Malka Zavitan, Carmit Cohen, Ilana Tal
Publikováno v:
The New England Journal of Medicine
Background Despite the high efficacy of the BNT162b2 messenger RNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rare breakthrough infections have been reported, including infections among health care workers. Data are
Autor:
Tal Zilberman-Daniels, Shoshi Segal, Mayan Gilboa, Einav G Levin, Ilana Tal, Asaf Biber, Ana Belkin, Gili Regev-Yochay, Carmit Rubin, Galia Rahav
Publikováno v:
Infection Control and Hospital Epidemiology
Objective:To assess reasons for noncompliance with COVID-19 vaccination among healthcare workers (HCWs).Design:Cohort observational and surveillance study.Setting:Sheba Medical Center, a 1,600-bed tertiary-care medical center in Israel.Participants:T
Autor:
Liraz Olmer, Menucha Jurkowicz, Yaniv Lustig, Sharon Halperin, Raanan Berger, Galia Rahav, Einav G Levin, Einat Shmueli, Ofer Margalit, Gili Regev-Yochay, Itzchak Levy, Amit Itay
Publikováno v:
European Journal of Cancer
Aim Patients with cancer are at an increased risk for severe coronavirus disease of 2019, thus data on the safety and efficacy of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines are essential. We conducted this prospective study
Autor:
Yaniv, Lustig, Ella, Mendelson, Michal, Mandelboim, Asaf, Biber, Einav G, Levin, Carmit, Cohen, Gili, Regev-Yochay, Eli, Schwartz
Publikováno v:
Clinical Infectious Diseases.
Approximately 1-8% of individuals do not develop antibodies following SARS-CoV-2 infection (sero-negatives). One BNT162b2 dose resulted in potent humoral response in 14 sero-negatives and 15 sero-positives, significantly higher than the response of 1
Autor:
Sharon Tzelnick, Einav G. Levin, Daniel Yacobi, Aviram Mizrachi, Aron Popovtzer, Ethan Soudry
Publikováno v:
American journal of rhinologyallergy.
Objective There is limited information regarding the recurrence patterns and efficacy of surveillance modalities in patients with sinonasal malignancies. Methods A retrospective study was conducted between the years 2001–2018 at a tertiary care cen
Autor:
Gili Regev-Yochay, Ofer Margalit, Liraz Olmer, Galia Rahav, Itzchak Levy, Menucha Jurkowicz, Yaniv Lustig, Einav G Levin, Amit Itay, Sharon Halperin, Einat Shacham-Shmueli, Raanan Berger
Publikováno v:
European journal of cancer (Oxford, England : 1990). 160
Autor:
Shlomi Toussia-Cohen, Gili Regev-Yochay, Carmit Cohen, Ram Doolman, Omer Nir, Anat Schwartz, Leah Leibovich, Sivan Sharabi, Keren Asraf, Einav G Levin, Tzipora Strauss, Yoav Yinon, Yaniv Lustig
Publikováno v:
American Journal of Obstetrics and Gynecology